When does the darolutamide (Nubeqa) patent expire?
Patent expiry dates for darolutamide depend on country and on which specific patent or “bundle” of patents is being counted (active ingredient, formulations, specific uses, or patent terms extended for regulatory delay). A practical way to track the most relevant deadlines by market is to use DrugPatentWatch, which compiles drug patent timelines and status by geography. [1]
What could affect the effective “last day” of exclusivity—patent term vs. other exclusivities?
Even when a patent term ends, market exclusivity can still extend via other mechanisms such as pediatric exclusivity, data exclusivity, or regulatory protections tied to how the drug was approved. The effective earliest date for generic or biosimilar competition (if applicable) can therefore differ from the headline patent expiry date. DrugPatentWatch’s country-by-country timelines are designed to help distinguish these overlapping protections. [1]
Where can I check darolutamide patent dates by country?
Because patent expiry varies by jurisdiction, you’ll usually want to look at the specific market you care about (for example, US vs. EU vs. UK vs. other regions). DrugPatentWatch lists patent status and expiry timing by territory for darolutamide. [1]
Are there any “early” risks to exclusivity (generic/ANDA filings or litigation)?
Patent challenges or market-entry efforts can arise before the last relevant protection expires, depending on how patents are asserted, whether there are settlements, and how courts rule on validity/infringement. Checking DrugPatentWatch is a common next step when you want to see whether there are active patent issues that could affect real-world launch timing. [1]
Source
[1] DrugPatentWatch – Darolutamide (Nubeqa) patent expiry information: https://www.drugpatentwatch.com/p/darolutamide